Quintela Fandiño, Miguel Angel miguel.quintela@uam.es
Actividades
- Artículos 52
- Libros 0
- Capítulos de libro 0
- Congresos 1
- Documentos de trabajo 0
- Informes técnicos 1
- Proyectos de investigación 0
- Tesis dirigidas 1
- Patentes o licencias de software 0
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
- Hitt, R
- Amador, ML
- Quintela-Fandino, M
- Jimeno, A
- del Val, O
- Hernando, S
- Cortes-Funes, H;
Cancer (p. 106-111) - 1/1/2006
10.1002/cncr.21579 Ver en origen
- ISSN 0008543X
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
- Quintela-Fandino, M.
- Krzyzanowska, M.
- Duncan, G.
- Young, A.
- Moore, M. J.
- Chen, E. X.
- Stathis, A.
- Colomer, R.
- Petronis, J.
- Grewal, M.
- Webster, S.
- Wang, L.
- Siu, L. L.;
British Journal Of Cancer (p. 1298-1305) - 2/4/2013
10.1038/bjc.2013.64 Ver en origen
- ISSN 00070920
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach
- Bueno, Maria J.
- Mouron, Silvana
- Quintela-Fandino, Miguel;
British Journal Of Cancer (p. 1119-1125) - 25/4/2017
10.1038/bjc.2017.69 Ver en origen
- ISSN 00070920
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
- Quintela-Fandino, M.
- Urruticoechea, A.
- Guerra, J.
- Gil, M.
- Gonzalez-Martin, A.
- Marquez, R.
- Hernandez-Agudo, E.
- Rodriguez-Martin, C.
- Gil-Martin, M.
- Bratos, R.
- Escudero, M. J.
- Vlassak, S.
- Hilberg, F.
- Colomer, R.;
British Journal Of Cancer (p. 1060-1064) - 1/1/2014
10.1038/bjc.2014.397 Ver en origen
- ISSN 00070920
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
- Quintela-Fandino M
- Holgado E
- Manso L
- Morales S
- Bermejo B
- Colomer R
- Apala JV
- Blanco R
- Muñoz M
- Caleiras E
- Iranzo V
- Martinez M
- Dominguez O
- Hornedo J
- Gonzalez-Cortijo L
- Cortes J
- Gasol Cudos A
- Malon D
- Lopez-Alonso A
- Moreno-Ortíz MC
- Mouron S
- Mañes S
Breast Cancer Research - 1/12/2020
10.1186/s13058-020-01362-y Ver en origen
- ISSN 14655411
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
- Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ
Breast Cancer Research (p. 21-21) - 1/12/2021
- ISSN 14655411
- iMarina
Nintedanib plus letrozole in early breast cancer: A phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
- Quintela-Fandino M
- Apala J
- Malon D
- Mouron S
- Hornedo J
- Gonzalez-Cortijo L
- Colomer R
- Guerra J
Breast Cancer Research - 24/5/2019
10.1186/s13058-019-1152-x Ver en origen
- ISSN 14655411
Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma
- Jimeno, A
- Hitt, R
- Quintela-Fandino, M
- Cortes-Funes, H;
Anti-Cancer Drugs (p. 53-57) - 1/1/2005
10.1097/00001813-200501000-00007 Ver en origen
- ISSN 14735741
Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
- Quintela-Fandino M
- Gravalos C
- Gonzalez E
- García-Velasco A
- Cortés-Funes H
Anti-Cancer Drugs (p. 31-38) - 1/1/2005
10.1097/00001813-200501000-00004 Ver en origen
- ISSN 14735741
Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
- Quintela-Fandino M
- Manso Sànchez LM
- Holgado Martín E
- Moreno MC
- Morales Murillo S
- Bermejo De Las Heras B
- Malon Gimenez D
- Colomer Bosch R
- Gonzalez Cortijo L
- Hornedo J
- Mouron S
- Muñoz M
- Escudero S
- Blanco R
- Mañes S
Annals Of Oncology - 1/11/2018
10.1093/annonc/mdy430.003 Ver en origen
- ISSN 09237534
Este/a investigador/a no tiene libros.
Este/a investigador/a no tiene capítulos de libro.
Phase I clinical trial of neoadjuvant BIBF1120 plus weekly paclitaxel (P) in early HER-2 negative breast cancer. CNIO-BR-01-2010 GEICAM 2010-10 study
- Quintela-Fandino, M.
- Urruticoechea, A.
- Guerra, J.
- Gil, M.
- Gonzalez-Martin, A.
- Marquez, R.
- Hernandez-Agudo, E.
- Rodriguez-Martin, C.
- Gil, M.
- Bratos, R.
- Escudero, M. J.
- Colomer, R.;
Cancer Research - 15/12/2013
10.1158/0008-5472.sabcs13-pd5-8 Ver en origen
- ISSN 00085472
Este/a investigador/a no tiene documentos de trabajo.
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K?/?, in Patients with Advanced Solid Tumors
- Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L, Shapiro GI, Siu LL, Hansen AR
Clinical Cancer Research (p. 2257-2269) - 1/1/2022
10.1158/1078-0432.ccr-21-3087 Ver en origen
- ISSN 15573265
Este/a investigador/a no tiene proyectos de investigación.
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Scopus Author ID
-
Dialnet id